Award
NIH Reporter #5UG3CA290454-02
Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers
Recipient
University of TX MD ANDERSON CANCER CENTER
Award Amount
$670,898.00
Ceiling
$670,898.00
Awarded
June 16, 2026
Identifier
5UG3CA290454-02
Development of a preventive vaccine for breast cancer in germline BRCA1/2 carriers using chimeric RNA derived neoantigens, validated in mouse models, aiming to provide a low-toxicity preventive approach.
Description
This project focuses on developing a preventive vaccine targeting neoantigens derived from chimeric mRNA in high-risk BRCA mutation carriers, utilizing bioinformatics and mouse models to validate efficacy. The research aims to revolutionize breast cancer prevention by integrating genomics, bioinformatics, and immunology to create an off-the-shelf vaccine applicable to women at high risk, with potential extension to other hereditary cancers.